Eisai Buys China Rights to GI Drug from Almirall

Eisai Co., Ltd., the fourth largest Japanese pharma, licensed the China rights to a gastroprokinetic agent, cinitapride tartrate, from Almirall, S.A. of Spain. Eisai obtained exclusive rights to develop, manufacture and market cinitapride in China. Eisai has a production facility in Suzhou. In 2001, Eisai bought the China rights to an antiallergic agent, Kestine, from Almirall. Terms of the new license were not disclosed. More details...